FDA Approved: EOVIST — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)

View source ↗

Summary

FDA approved Bayer's supplemental application for EOVIST (gadoxetate disodium), updating its labeling related to use in MRI for detecting focal liver lesions.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• EOVIST (GADOXETATE DISODIUM)

Snippet

SUPPL AP for EOVIST (GADOXETATE DISODIUM)